# Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

> **NCT02454179** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 78 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT02454179
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-05
- **Final completion:** 2018-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454179, "Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02454179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*